 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 August 1996 | Volume 125 Issue 4 | Pages 311-323
Purpose: To review the efficacy and safety of electrical and pharmacologic conversion of atrial fibrillation, strategies for maintenance of sinus rhythm, and the importance of antithrombotic therapy.
Data Sources: English-language trials were identified from the MEDLINE database through 1995, bibliographic references, Current Contents, textbooks, and recent abstracts.
Study Selection: Randomized trials (including abstracts) were selected. Cohort studies were used if randomized trials were not available.
Data Extraction: Study design and data were extracted from clinical trials. Statistical analysis of combined data was not appropriate, given the marked variations in study designs and study populations.
Data Synthesis: Cardioversion restores sinus rhythm in more than 80% of patients. In atrial fibrillation of recent onset, pharmacologic regimens have a success rate of 40% to 90%. Sinus rhythm at 1 year is maintained in 30% of patients without antiarrhythmic therapy but in 50% of patients with such therapy. The efficacy and safety of antiarrhythmic drugs relative to one another are not established because trials done to date have been small and cases vary. Successful cardioversion and maintenance of sinus rhythm are most predictable when the duration of atrial fibrillation is brief.
Warfarin reduces the incidence of ischemic strokes and emboli in patients with nonvalvular atrial fibrillation from 4.5% to 1.4% per year. Aspirin (325 mg/d) appears to be equally effective in patients younger than 75 years of age who do not have hypertension or a history of thromboembolism or recent heart failure. Although warfarin is more effective than aspirin in preventing embolic strokes in patients older than 75 years of age, it may increase the incidence of hemorrhagic stroke and result in a similar rate of disabling stroke.
Conclusion: Cardioversion remains the preferred method with which to re-establish sinus rhythm. Long-term antiarrhythmic therapy is warranted only if recurrences or initial clinical instability are seen; pro-arrhythmic concerns and potential side effects should guide drug selection. Antithrombotic therapy is indicated for all patients older than 60 years of age and in all patients younger than 60 years of age who have clinical evidence of a primary cardiac disorder.
Author and Article Information
From Case Western Reserve University and MetroHealth Medical Center, Cleveland, Ohio.
REVIEW
Atrial Fibrillation: Restoration and Maintenance of Sinus Rhythm and Indications for Anticoagulation Therapy
Acknowledgments: The authors thank Carol Smith for help with manuscript preparation, Dr. Louis Rakita for his helpful review, and the Brittingham Library Staff of MetroHealth Medical Center for their professional support.
Requests for Reprints: Robert C. Bahler, MD, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109-1998.
Current Author Addresses: Dr. Golzari: 307-B Essex Street, Hackensack, NJ 07601.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  J. F. Doyle and K. M. Ho Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis Mayo Clin. Proc., March 1, 2009; 84(3): 234 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Voeller, R. B. Schuessler, and R. J. Damiano Jr. Surgical Treatment of Atrial Fibrillation Card. Surg. Adult, January 1, 2008; 3(2008): 1375 - 1394. [Full Text]
|
|
|
|
 |
|
 C. Lafuente-Lafuente, S. Mouly, M. A. Longas-Tejero, I. Mahe, and J.-F. Bergmann Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med, April 10, 2006; 166(7): 719 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Marshall, A. R. Levy, H. Vidaillet, E. Fenwick, A. Slee, G. Blackhouse, H. L. Greene, D. G. Wyse, G. Nichol, B. J. O'Brien, et al. Cost-Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation Ann Intern Med, November 2, 2004; 141(9): 653 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kang, B. J. Daly, and J.-S. Kim Uncertainty and Its Antecedents in Patients With A trial Fibrillation West J Nurs Res, November 1, 2004; 26(7): 770 - 783. [Abstract] [PDF]
|
|
|
|
 |
|
 K. K Anthony and V. F Mauro Rate Versus Rhythm Control in Atrial Fibrillation Ann. Pharmacother., May 1, 2004; 38(5): 839 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Dowd Anticoagulation in the Elderly Journal of Pharmacy Practice, April 1, 2004; 17(2): 94 - 102. [Abstract] [PDF]
|
|
|
|
 |
|
 R. R Kasliwal, S. Mukesh, G. Manohar, N. Aggarwal, and A. Bhatia Pharmacotherapy of Atrial Fibrillation Asian Cardiovasc Thorac Ann, December 1, 2003; 11(4): 364 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gronefeld and S. H. Hohnloser Rhythm or Rate Control in Atrial Fibrillation: Insights from the Randomized Controlled Trials Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1_suppl): S39 - S44. [Abstract] [PDF]
|
|
|
|
 |
|
 A. L. Klein, R. D. Murray, and R. A. Grimm Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation J. Am. Coll. Cardiol., March 1, 2001; 37(3): 691 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Khan Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation J. Am. Coll. Cardiol., February 1, 2001; 37(2): 542 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Kajubi Additional Monitoring Tools to Improve the Quality of Anticoagulation Management Arch Intern Med, October 23, 2000; 160(19): 3006 - 3006. [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Gage, M. Boechler, A. L. Doggette, G. Fortune, G. C. Flaker, M. W. Rich, and M. J. Radford Adverse Outcomes and Predictors of Underuse of Antithrombotic Therapy in Medicare Beneficiaries With Chronic Atrial Fibrillation Stroke, April 1, 2000; 31(4): 822 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Feldman, N. Campbell, P. Larochelle, P. Bolli, E. D. Burgess, S. G. Carruthers, J. S. Floras, R. B. Haynes, G. Honos, F. H.H. Leenen, et al. 1999 Canadian recommendations for the management of hypertension Can. Med. Assoc. J., December 14, 1999; 161(90120): S1 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Eckman, R. H. Falk, and S. G. Pauker Cost-effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation Arch Intern Med, August 10, 1998; 158(15): 1669 - 1677. [Abstract] [Full Text]
|
|
|
|
|
|
B. F. Gage, A. B. Cardinalli, and D. K. Owens Cost-Effectiveness of Preference-Based Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation Stroke, June 1, 1998; 29(6): 1083 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-G. Li and S. H. Hohnloser Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 185 - 194. [Abstract] [PDF]
|
|
|
|
 |
|
 R. J. Ackermann Anticoagulant Therapy in Patients Aged 80 Years or More With Atrial Fibrillation: More Caution Is Needed Arch Fam Med, March 1, 1997; 6(2): 105 - 110. [Abstract] [PDF]
|
|
